A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles

Zariwala, M.; El-Said, N.; Jackson, Timothy L.; López, Francisco Corral; Farnaud, Sébastien; Somavarapu, Satyanarayana; Renshaw, Derek

doi:10.1016/j.ijpharm.2013.08.070

Cited by 70 publications

(50 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On comparing iron oxide nanoparticles group with ferrous sulfate group, there was significant decrease in total iron binding capacity that ascertain the effectiveness of iron oxide nanoparticles than ferrous sulfate in treating anemia. Our result matched with Shafie et al and Zariwala et al [4,17]. In addition, there was a significant decrease in serum MDA level in iron oxide nanoparticle group when compared to ferrous sulfate group which confirms the effectiveness of iron oxide nanoparticles to remove the oxidative stress which may be due to the production of free radicals by ferrous sulfate through Fenton reaction that is made by the remaining free iron unabsorbed from ferrous sulfate [18].…”

Section: Discussionsupporting

confidence: 91%

Iron Oxide Nanoparticles Versus Ferrous Sulfate In Treatment of Iron Deficiency Anemia In Rats

Elshemy

2018

NIDOC-ASRT

View full text Add to dashboard Cite

F errous sulfate is the most commonly used drug for treatment of iron deficiency anemia, but it is badly absorbed and causes many unfavorable side effects. Nanotechnology is a way to decrease the side effects of drugs and to increase the drug bioavailability. So, this study is designed to investigate the effect of iron oxide nanoparticles in comparison to ferrous sulphate in the treatment of iron deficiency anemia in rats. Forty male albino rats were divided into two main groups: Control group (10 rats) and anemic group (30 rats) that received standard iron free basal diet for six weeks. Then the anemic group was subdivided into three groups (10 rats) in each group: anemic control group, ferrous sulfate group (received ferrous sulfate 0.4 mg/ kg b.w/ 10 days) and iron oxide nanoparticles group (received iron oxide nanoparticles 0.4 mg/ kg b.w/ 10 days) in the drinking water. Iron oxide nanoparticlescaused a significant increase in the level of red blood cells (8.80±0.05 10 6 /µL), hemoglobin (18.46±0.33 g/dL), hematocrit (46.66±0.23 %), mean corpuscular volume (MCV) (53.02±0.3 FL), mean corpuscular hemoglobin concentration (MCHC) (39.56±0.6 %), ferritin (447.6±9.02 µg/L), transferrin saturation (138.0±1.5), total iron binding capacity (TIBC) (145.00±1.15 mg/dL) and serum iron (276.33±2.07 mg/dL). Moreover, it decreased serum malondialdehyde (MDA) (31.85±0.34 nmol/g) and C-reactive protein (CRP) (312.66±1.7 mg/L) when compared to ferrous sulfate group and anemia control groups. These results revealed that iron oxide nanoparticles proved as an effective drug for the treatment of iron deficiency anemia in rats.

show abstract

Section: Discussionsupporting

confidence: 91%

Iron Oxide Nanoparticles Versus Ferrous Sulfate In Treatment of Iron Deficiency Anemia In Rats

Elshemy

2018

NIDOC-ASRT

View full text Add to dashboard Cite

show abstract

“…It was observed that increasing the concentration of ferrous iron as a percentage (w/w) of the encapsulating material led to a gradual decrease in iron entrapment, with an initial iron loading at 10% concentration resulting in as little as 3% entrapment [35]. Chitosan concentration in the nanocarrier was also optimised in a previous work performed by the authors [35]. This is in agreement with previous studies that have reported a correlation between decreased iron entrapment and high initial ferrous iron concentration.…”

Section: Preparation and Iron Entrapment Efficiency Of Ascorbyl Palmisupporting

confidence: 83%

“…Aliquots of nanocarrier dispersions were subjected to ultracentrifugation (11336 g, 60 minutes, 4 ºC) in a refrigerated laboratory centrifuge (Heraeus Fresco 70, Thermo Fisher, UK). The supernatant was collected and iron concentrations determined using the iron chelator ferrozine [33] as previously described , [34,35], and measuring the absorbance of the coloured complex spectrophotometrically at 562 using a microplate reader (VersaMax, Molecular Devices, USA) [33]. Measurements were repeated in triplicate, and results expressed as means ± standard deviations.…”

Section: Iron Entrapmentmentioning

confidence: 99%

“…Prior to conducting these experiments optimisation experiments were carried out to determine the initial amount of iron to be added. It was observed that increasing the concentration of ferrous iron as a percentage (w/w) of the encapsulating material led to a gradual decrease in iron entrapment, with an initial iron loading at 10% concentration resulting in as little as 3% entrapment [35]. Chitosan concentration in the nanocarrier was also optimised in a previous work performed by the authors [35].…”

Section: Preparation and Iron Entrapment Efficiency Of Ascorbyl Palmimentioning

confidence: 99%

See 1 more Smart Citation

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Zariwala

Farnaud

Merchant

et al. 2014

Colloids and Surfaces B: Biointerfaces

Self Cite

View full text Add to dashboard Cite

“…Zariwala et al [16] prepared solid lipid nanoparticles loaded with ferrous sulphate by the double emulsion solvent evaporation process. Solid lipid nanoparticles are widely used in drug targeting and delivery because of the multi-fold advantages they provide.…”

Section: Nanotechnology For Iron Deficiency Anaemiamentioning

confidence: 99%

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

Shukla

Dasgupta

Ranjan

et al. 2017

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

The application of nanotechnology in medicine, diagnostics, therapeutics, drug delivery, etc. in order to overcome the limitations faced by these fields has already been established. Anaemia and osteoporosis are two of the most widely prevalent iron and calcium deficiency diseases among women. Conventional drugs for both have their inherent limitations which can be overcome by nanotechnology. Nanonization of drugs has been established as a very efficient way to enhance the bioavailability and absorption of the drug in the gastrointestinal tract. In addition to this, encapsulation of drugs in solid lipid nanoparticles is also employed to increase the stability of the drug in the gastrointestinal tract and to facilitate its controlled release. Nanotechnology is also applied in bone tissue engineering to prepare bone grafts for bone injury. Nanotechnology-based bone grafts have shown to possess enhanced mechanical properties and better biocompatibility and osteoconduction than the conventional bone grafts. This review article highlights the research trends and challenges of nanotechnology based drugs to combat iron deficiency anaemia and osteoporosis. This review outlines the recent research trends in nano-drugs and touches on issues concerning the market, industries and patents pertaining to drugs for anaemia and osteoporosis. To provide the safety and risk factors of nanomaterials, we have briefly highlighted the toxicological aspects of nanomaterials used in drugs.

show abstract

A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles

Cited by 70 publications

References 61 publications

Iron Oxide Nanoparticles Versus Ferrous Sulfate In Treatment of Iron Deficiency Anemia In Rats

Iron Oxide Nanoparticles Versus Ferrous Sulfate In Treatment of Iron Deficiency Anemia In Rats

Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: Preparation, characterisation and in vitro evaluation

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

Contact Info

Product

Resources

About